SCHEMBL20129067

SCHEMBL20129067

Cn1c2ccncc2c2ccc(-c3ccc(OCCCCOCCCCO)nc3)cc21

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.37
ATM Q13315 14/20 0.37
PDE5A O76074 2/20 0.37
PDE6A P16499 2/20 0.37
PIK3CA P42336 4/20 0.35
MTOR P42345 4/20 0.35
ATR Q13535 3/20 0.35
PIK3CD O00329 1/20 0.35
PIK3CB P42338 1/20 0.35
PI4KA P42356 1/20 0.35
PIK3CG P48736 1/20 0.35
PI4KB Q9UBF8 1/20 0.35
NPC1 O15118 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
RAB9A P51151 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
GCK P35557 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27097805 0.99 METAP2 (0.37) METAP2ATMPDE5APDE6APIK3CA
SCHEMBL20128973 0.99 METAP2 (0.37) METAP2ATMPDE5APDE6APIK3CA
SCHEMBL20129125 0.94 ATM (0.39) METAP2ATMPDE5APDE6APIK3CA
SCHEMBL20128994 0.92 PDE5A (0.34) METAP2ATMPDE5APDE6APIK3CA
SCHEMBL20129094 0.91 PIK3CA (0.38) METAP2ATMPDE5APDE6APIK3CA
SCHEMBL30479974 0.91 PIK3CA (0.38) METAP2ATMPDE5APDE6APIK3CA
SCHEMBL20423270 0.91 PIK3CA (0.38) METAP2ATMPDE5APDE6APIK3CA
SCHEMBL20129066 0.87 METAP2 (0.38) METAP2ATMPIK3CAMTORATR
SCHEMBL20128971 0.86 ATM (0.38) METAP2ATMPIK3CAMTORATR
SCHEMBL27097804 0.86 ATM (0.38) METAP2ATMPIK3CAMTORATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 METAP2 954/4885ATM 959/4885PDE5A 4425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.